

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 September 2020 (03.09.2020)



(10) International Publication Number
WO 2020/176776 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) C12Q 1/68 (2018.01)
C12N 15/11 (2006.01)

(21) International Application Number:

PCT/US2020/020175

(22) International Filing Date:

27 February 2020 (27.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/811,511 27 February 2019 (27.02.2019) US

(71) Applicant: **STOKE THERAPEUTICS, INC.** [US/US];
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).

(72) Inventor: **AZNAREZ, Isabel**; 196 Chestnut Avenue, Unit
B, Boston, Massachusetts 02130 (US).

(74) Agent: **SHARMA, Swati T.**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES




FIG. 1A

(57) Abstract: Alternative splicing events in *SCN1A* gene can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in *SCN1A* gene can modulate the expression level of functional proteins in Dravet Syndrome patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition caused by *SCN1A*, *SCN8A* or *SCN5A* protein deficiency.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*